@article{10701, keywords = {Humans, Hypoglycemic Agents/adverse effects, *Diabetes Mellitus, Type 2/drug therapy, *Dipeptidyl-Peptidase IV Inhibitors/adverse effects, *Sodium-Glucose Transporter 2 Inhibitors/adverse effects, Glucagon-Like Peptide-1 Receptor/agonists, Cohort Studies, Sulfonylurea Compounds/adverse effects, *Pulmonary Disease, Chronic Obstructive/drug therapy}, author = {R. Pradhan and S. Lu and H. Yin and O. H. Y. Yu and P. Ernst and S. Suissa and L. Azoulay}, title = {Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study}, year = {2022}, journal = {Bmj}, volume = {379}, edition = {2022/11/02}, pages = {e071380}, isbn = {0959-8138 (Print) 0959-8138}, doi = {10.1136/bmj-2022-071380}, note = {1756-1833 Pradhan, Richeek Lu, Sally Yin, Hui Yu, Oriana H Y Ernst, Pierre Suissa, Samy Azoulay, Laurent Orcid: 0000-0001-5162-3556 Journal Article England BMJ. 2022 Nov 1;379:e071380. doi: 10.1136/bmj-2022-071380.}, language = {eng}, }